Abstract

Ocular myasthenia gravis (OMG) is a localized form of myasthenia gravis in which autoantibodies directed against acetylcholine receptors block or destroy these receptors at the postsynaptic neuromuscular junction. The hallmark of OMG is a history of painless weakness or fatigability of the extraocular muscles and ptosis with normal pupillary function and visual acuity. Clinical, laboratory, electrophysiologic, and pharmacologic tests are available for diagnosis. Treatment can begin with symptom management; there is no cure. Prognosis is improved by use of immunomodulators. Despite advances in treatment, research is needed, especially in the areas of surgical intervention and medical therapy based on risk stratification.

Original languageEnglish (US)
Pages (from-to)115-123
Number of pages9
JournalNeurologic Clinics
Volume35
Issue number1
DOIs
StatePublished - Feb 1 2017

Keywords

  • Autoimmune disease
  • Diplopia
  • Myasthenia gravis
  • Neuromuscular junction disorder
  • Ophthalmoplegia
  • Ptosis
  • Weakness

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Update on Ocular Myasthenia Gravis'. Together they form a unique fingerprint.

Cite this